SCHEMBL6282939

SCHEMBL6282939

CC(C)CN1C(=O)N(C(=O)c2ccc3ccccc3c2)C(=O)C1(c1ccccc1)c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 1/20 0.40
CBX7 O95931 1/20 0.39
CDYL2 Q8N8U2 1/20 0.39
CDYL Q9Y232 1/20 0.39
CDY1; CDY1B Q9Y6F8 1/20 0.39
TSHR P16473 2/20 0.38
HPGD P15428 1/20 0.38
ENPP3 O14638 2/20 0.37
ALPL P05186 2/20 0.37
XIAP P98170 2/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
LMNA P02545 1/20 0.37
DRD4 P21917 1/20 0.36
HTR1A P08908 1/20 0.36
HTR7 P34969 1/20 0.36
HTR6 P50406 1/20 0.36
KMT2A Q03164 2/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6287762 0.85 BCHE (0.41) BCHECBX7CDYL2CDYLCDY1; CDY1B
SCHEMBL6282035 0.85 BCHE (0.42) BCHECBX7CDYL2CDYLCDY1; CDY1B
SCHEMBL6283118 0.84 NPC1 (0.49) BCHECBX7CDYL2CDYLCDY1; CDY1B
SCHEMBL6284743 0.81 TSHR (0.46) BCHECBX7CDYL2CDYLCDY1; CDY1B
SCHEMBL6287739 0.81 TSHR (0.39) BCHETSHRHPGDENPP3ALPL
SCHEMBL6282932 0.80 CDYL (0.42) BCHECBX7CDYLCDY1; CDY1BHTR1A
SCHEMBL6285250 0.77 CBX7 (0.40) BCHECBX7CDYL2CDYLCDY1; CDY1B
SCHEMBL6282913 0.76 KMT2A (0.46) BCHECBX7CDYL2CDYLCDY1; CDY1B
SCHEMBL6283097 0.75 CBX7 (0.42) BCHECBX7CDYL2CDYLCDY1; CDY1B
SCHEMBL6282090 0.74 KMT2A (0.46) BCHECBX7CDYL2CDYLCDY1; CDY1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919365-B2 Imidazolidinedione derivatives and use thereof as drugs SENJU PHARMACEUTICAL CO., LTD. (JP) 2005-07-19 US disclosed
US-20040110811-A1 Novel imidazolidinedione derivatives and use thereof as drugs SENJU PHARMACEUTICAL CO., LTD. (JP) 2004-06-10 US disclosed
EP-1384715-A1 NOVEL IMIDAZOLIDINEDIONE DERIVATIVES AND USE THEREOF AS DRUGS Senju Pharmaceutical Co., Ltd. (JP) 2004-01-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110811-A1 Novel imidazolidinedione derivatives and use thereof as drugs CMA1, TPSD1, TPSB2 BCHE 515/4885CBX7 2579/4885CDYL2 3565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.